Albert Robichaud - 03 Feb 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Scientific Officer
Signature
/s/ Anne Marie Cook, as Attorney-in-Fact for Albert Robichaud
Issuer symbol
SAGE
Transactions as of
03 Feb 2023
Net transactions value
-$49,768
Form type
4
Filing time
07 Feb 2023, 15:11:12 UTC
Previous filing
15 Feb 2022
Next filing
15 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +3,375 +2.4% $0.000000 146,680 03 Feb 2023 Direct F1, F2
transaction SAGE Common Stock Tax liability $49,768 -1,127 -0.77% $44.16 145,553 03 Feb 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 11,250 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 3,375 shares.
F2 Reflects beneficial ownership balance which includes 279 shares purchased on June 30, 2022 and 397 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.